-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On February 28, Huadong Medicine announced that the company has reached a series of strategic cooperation agreements with Heidelberg Pharma, a German listed company, and signed relevant agreements with relevant parties
.
Among them, the "Equity Investment Agreement" shows that Huadong Medicine subscribes for the shares issued by Heidelberg Pharma at a price of 6.
44 euros per share and acquires part of the equity from the counterparty to obtain a 35% stake in Heidelberg Pharma, becoming its second largest company.
Shareholder, the equity investment amounted to 105 million euros
.
According to the data, Heidelberg Pharma (formerly WILEX AG), founded in 1997, is a global biopharmaceutical company focusing on the research and development of oncology ADC drugs
.
The company has a proprietary ATAC technology platform and is the first company in the world to successfully develop Amanitin (Amanita) and its derivatives for cancer therapy, and has successfully exploited the unique biological properties of the toxin to create a new treatment
.
Another agreement on product licensing shows that Huadong Huadong, a wholly-owned subsidiary of Huadong Medicine, will obtain the exclusive license of HDP-101 and HDP-103, two products under development owned by Heidelberg Pharma, in 20 Asian countries and regions.
Includes exclusive development and commercialization rights
.
According to the agreement, Zhongmei Huadong will pay Heidelberg Pharma an upfront payment of US$20 million, development, registration and sales milestone payments of up to US$449 million, as well as royalties on net sales
.
It is understood that the two products under development, HDP-101 and HDP-103, owned by Heidelberg Pharma have many highlights
.
Among them, HDP-101 is an ATAC (Antibody-Amanita Conjugate) drug targeting B cell maturation antigen (BCMA), with strong anti-tumor activity and good tolerance
.
The drug is undergoing an overseas Phase I/IIa clinical trial for the treatment of relapsed/refractory multiple myeloma, and the first subject has been administered on February 15, 2022
.
HDP-103 is an ATAC drug targeting prostate-specific membrane antigen (PSMA) and is undergoing preclinical research for the indication of metastatic castration-resistant prostate cancer (mCRPC)
.
In addition to the above-mentioned two products under development, the exclusive right to choose HDP-102 and HDP-104 of Heidelberg Pharma's under-development products will also be owned by Zhongmei Huadong
.
Among them, HDP-102 is an ATAC drug targeting CD37, which is undergoing preclinical research and the target indication is non-Hodgkin's lymphoma (NHL)
.
The HDP-104 target has not been disclosed, and preclinical studies are underway
.
According to the cooperation agreement, Zhongmei Huadong also has the right of first negotiation (ROFN) for two other follow-up products under development of Heidelberg Pharma
.
It is understood that the field of oncology is a strategic field that Huadong Medicine focuses on.
The company has many years of experience in the development and industrialization of oncology drugs.
At present, a number of anti-tumor products have been launched, and new achievements have been continuously achieved
.
For example, Huadong Medicine recently achieved the primary endpoint of the US pivotal single-arm clinical trial (SORAYA trial) of Mirvetuximab, the world's first ADC drug candidate for folate receptor alpha (FRα)-positive ovarian cancer, and is expected to launch the product in China positive impact on registration declarations
.
At present, the product has completed the enrollment and administration of the first subject in the PK pharmacokinetic study of the Phase I clinical trial in China
.
In recent years, Huadong Medicine has continued to focus on in-depth and differentiated layout in the field of oncology, focusing on clinical needs and patients, and has successively cooperated with a number of domestic and foreign innovative R&D companies
.
Not long ago, Huadong Medicine cooperated with AKSO Biopharmaceutical, an American pharmaceutical company, and Huadong Medicine planned to acquire the latter's researched global innovative drug AB002 (for solid tumor treatment) in the Asia-Pacific region (except Japan) for no more than US$75 million.
Exclusive clinical development and commercialization rights
.
It is foreseeable that, through this "hand in hand", Huadong Medicine's layout in the field of anti-tumor drugs will take a higher level
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, the "Equity Investment Agreement" shows that Huadong Medicine subscribes for the shares issued by Heidelberg Pharma at a price of 6.
44 euros per share and acquires part of the equity from the counterparty to obtain a 35% stake in Heidelberg Pharma, becoming its second largest company.
Shareholder, the equity investment amounted to 105 million euros
.
According to the data, Heidelberg Pharma (formerly WILEX AG), founded in 1997, is a global biopharmaceutical company focusing on the research and development of oncology ADC drugs
.
The company has a proprietary ATAC technology platform and is the first company in the world to successfully develop Amanitin (Amanita) and its derivatives for cancer therapy, and has successfully exploited the unique biological properties of the toxin to create a new treatment
.
Another agreement on product licensing shows that Huadong Huadong, a wholly-owned subsidiary of Huadong Medicine, will obtain the exclusive license of HDP-101 and HDP-103, two products under development owned by Heidelberg Pharma, in 20 Asian countries and regions.
Includes exclusive development and commercialization rights
.
According to the agreement, Zhongmei Huadong will pay Heidelberg Pharma an upfront payment of US$20 million, development, registration and sales milestone payments of up to US$449 million, as well as royalties on net sales
.
It is understood that the two products under development, HDP-101 and HDP-103, owned by Heidelberg Pharma have many highlights
.
Among them, HDP-101 is an ATAC (Antibody-Amanita Conjugate) drug targeting B cell maturation antigen (BCMA), with strong anti-tumor activity and good tolerance
.
The drug is undergoing an overseas Phase I/IIa clinical trial for the treatment of relapsed/refractory multiple myeloma, and the first subject has been administered on February 15, 2022
.
HDP-103 is an ATAC drug targeting prostate-specific membrane antigen (PSMA) and is undergoing preclinical research for the indication of metastatic castration-resistant prostate cancer (mCRPC)
.
In addition to the above-mentioned two products under development, the exclusive right to choose HDP-102 and HDP-104 of Heidelberg Pharma's under-development products will also be owned by Zhongmei Huadong
.
Among them, HDP-102 is an ATAC drug targeting CD37, which is undergoing preclinical research and the target indication is non-Hodgkin's lymphoma (NHL)
.
The HDP-104 target has not been disclosed, and preclinical studies are underway
.
According to the cooperation agreement, Zhongmei Huadong also has the right of first negotiation (ROFN) for two other follow-up products under development of Heidelberg Pharma
.
It is understood that the field of oncology is a strategic field that Huadong Medicine focuses on.
The company has many years of experience in the development and industrialization of oncology drugs.
At present, a number of anti-tumor products have been launched, and new achievements have been continuously achieved
.
For example, Huadong Medicine recently achieved the primary endpoint of the US pivotal single-arm clinical trial (SORAYA trial) of Mirvetuximab, the world's first ADC drug candidate for folate receptor alpha (FRα)-positive ovarian cancer, and is expected to launch the product in China positive impact on registration declarations
.
At present, the product has completed the enrollment and administration of the first subject in the PK pharmacokinetic study of the Phase I clinical trial in China
.
In recent years, Huadong Medicine has continued to focus on in-depth and differentiated layout in the field of oncology, focusing on clinical needs and patients, and has successively cooperated with a number of domestic and foreign innovative R&D companies
.
Not long ago, Huadong Medicine cooperated with AKSO Biopharmaceutical, an American pharmaceutical company, and Huadong Medicine planned to acquire the latter's researched global innovative drug AB002 (for solid tumor treatment) in the Asia-Pacific region (except Japan) for no more than US$75 million.
Exclusive clinical development and commercialization rights
.
It is foreseeable that, through this "hand in hand", Huadong Medicine's layout in the field of anti-tumor drugs will take a higher level
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
